Allergan plc, of Dublin, and Gedeon Richter plc, of Budapest, Hungary, provided a clinical and regulatory update on cariprazine, approved by the FDA in September 2015 and marketed as Vraylar in the U.S. for the treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adults.